Accutar Biotechnology, Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Accutar Biotechnology, Inc.
Genentech Licenses Prostate Cancer Drug From China-Based Jemincare
Deal Snapshot: Other major players have made headway in bispecifics for prostate cancer, while Jemincare’s drug is the latest China-developed technology to head westward.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.